ABN Newswire -- Australia’s regenerative medicine company, Mesoblast Limited, today announced that institutional and sophisticated investors have made a minimum of A$7 million and up to a maximum of A$10 million equity-based investment in its United States associate company, Angioblast Systems Inc. Settlement formalities are expected to be completed in the next seven days.
